FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284694766> ?p ?o ?g. }

• W4284694766 endingPage "e0270950" @default.
• W4284694766 startingPage "e0270950" @default.
• W4284694766 abstract "Introduction The spleen is a lymphoid organ and we hypothesize that clinical benefit to immunotherapy may present with an increase in splenic volume during treatment. The purpose of this study was to investigate whether changes in splenic volume could be observed in those showing clinical benefit versus those not showing clinical benefit to pembrolizumab treatment in non-small cell lung cancer (NSCLC) patients. Materials and methods In this study, 70 patients with locally advanced or metastatic NSCLC treated with pembrolizumab; and who underwent baseline CT scan within 2 weeks before treatment and follow-up CT within 3 months after commencing immunotherapy were retrospectively evaluated. The splenic volume on each CT was segmented manually by outlining the splenic contour on every image and the total volume summated. We compared the splenic volume in those achieving a clinical benefit and those not achieving clinical benefit, using non-parametric Wilcoxon signed-rank test. Clinical benefit was defined as stable disease or partial response lasting for greater than 24 weeks. A p-value of <0.05 was considered statistically significant. Results There were 23 responders and 47 non-responders based on iRECIST criteria and 35 patients with clinical benefit and 35 without clinical benefit. There was no significant difference in the median pre-treatment volume (175 vs 187 cm 3 , p = 0.34), post-treatment volume (168 vs 167 cm 3 , p = 0.39) or change in splenic volume (-0.002 vs 0.0002 cm 3 , p = 0.97) between the two groups. No significant differences were also found between the splenic volume of patients with partial response, stable disease or progressive disease (p>0.017). Moreover, there was no statistically significant difference between progression-free survival and time to disease progression when the splenic volume was categorized as smaller or larger than the median pre-treatment or post-treatment volume (p>0.05). Conclusion No significant differences were observed in the splenic volume of those showing clinical benefit versus those without clinical benefit to pembrolizumab treatment in NSCLC patients. CT splenic volume cannot be used as a potentially simple biomarker of response to immunotherapy." @default.
• W4284694766 created "2022-07-08" @default.
• W4284694766 creator A5001503641 @default.
• W4284694766 creator A5025403444 @default.
• W4284694766 creator A5037269194 @default.
• W4284694766 creator A5040106089 @default.
• W4284694766 creator A5048179253 @default.
• W4284694766 creator A5068540628 @default.
• W4284694766 creator A5073795960 @default.
• W4284694766 creator A5080623230 @default.
• W4284694766 date "2022-07-07" @default.
• W4284694766 modified "2023-10-16" @default.
• W4284694766 title "Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy" @default.
• W4284694766 cites W1982488143 @default.
• W4284694766 cites W2005251163 @default.
• W4284694766 cites W2047154154 @default.
• W4284694766 cites W2060813234 @default.
• W4284694766 cites W2063192133 @default.
• W4284694766 cites W2096616470 @default.
• W4284694766 cites W2101957891 @default.
• W4284694766 cites W2120044571 @default.
• W4284694766 cites W2143007780 @default.
• W4284694766 cites W2171082305 @default.
• W4284694766 cites W2198093519 @default.
• W4284694766 cites W2281692823 @default.
• W4284694766 cites W2484653942 @default.
• W4284694766 cites W2515818241 @default.
• W4284694766 cites W2527905628 @default.
• W4284694766 cites W2529904548 @default.
• W4284694766 cites W2560367415 @default.
• W4284694766 cites W2572174216 @default.
• W4284694766 cites W2592144107 @default.
• W4284694766 cites W2742193031 @default.
• W4284694766 cites W2749460173 @default.
• W4284694766 cites W2773643507 @default.
• W4284694766 cites W2776881166 @default.
• W4284694766 cites W2789932412 @default.
• W4284694766 cites W2791483720 @default.
• W4284694766 cites W2796582438 @default.
• W4284694766 cites W2902968854 @default.
• W4284694766 cites W2904105095 @default.
• W4284694766 cites W2910245285 @default.
• W4284694766 cites W2940611353 @default.
• W4284694766 cites W2945464379 @default.
• W4284694766 cites W3026905936 @default.
• W4284694766 cites W3044807957 @default.
• W4284694766 cites W3106818633 @default.
• W4284694766 cites W3182103728 @default.
• W4284694766 cites W4225674020 @default.
• W4284694766 doi "https://doi.org/10.1371/journal.pone.0270950" @default.
• W4284694766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35797413" @default.
• W4284694766 hasPublicationYear "2022" @default.
• W4284694766 type Work @default.
• W4284694766 citedByCount "2" @default.
• W4284694766 countsByYear W42846947662023 @default.
• W4284694766 crossrefType "journal-article" @default.
• W4284694766 hasAuthorship W4284694766A5001503641 @default.
• W4284694766 hasAuthorship W4284694766A5025403444 @default.
• W4284694766 hasAuthorship W4284694766A5037269194 @default.
• W4284694766 hasAuthorship W4284694766A5040106089 @default.
• W4284694766 hasAuthorship W4284694766A5048179253 @default.
• W4284694766 hasAuthorship W4284694766A5068540628 @default.
• W4284694766 hasAuthorship W4284694766A5073795960 @default.
• W4284694766 hasAuthorship W4284694766A5080623230 @default.
• W4284694766 hasBestOaLocation W42846947661 @default.
• W4284694766 hasConcept C121608353 @default.
• W4284694766 hasConcept C126322002 @default.
• W4284694766 hasConcept C141071460 @default.
• W4284694766 hasConcept C143998085 @default.
• W4284694766 hasConcept C2776256026 @default.
• W4284694766 hasConcept C2777701055 @default.
• W4284694766 hasConcept C2780057760 @default.
• W4284694766 hasConcept C71924100 @default.
• W4284694766 hasConcept C90924648 @default.
• W4284694766 hasConceptScore W4284694766C121608353 @default.
• W4284694766 hasConceptScore W4284694766C126322002 @default.
• W4284694766 hasConceptScore W4284694766C141071460 @default.
• W4284694766 hasConceptScore W4284694766C143998085 @default.
• W4284694766 hasConceptScore W4284694766C2776256026 @default.
• W4284694766 hasConceptScore W4284694766C2777701055 @default.
• W4284694766 hasConceptScore W4284694766C2780057760 @default.
• W4284694766 hasConceptScore W4284694766C71924100 @default.
• W4284694766 hasConceptScore W4284694766C90924648 @default.
• W4284694766 hasIssue "7" @default.
• W4284694766 hasLocation W42846947661 @default.
• W4284694766 hasLocation W42846947662 @default.
• W4284694766 hasLocation W42846947663 @default.
• W4284694766 hasLocation W42846947664 @default.
• W4284694766 hasOpenAccess W4284694766 @default.
• W4284694766 hasPrimaryLocation W42846947661 @default.
• W4284694766 hasRelatedWork W2047967234 @default.
• W4284694766 hasRelatedWork W2439875401 @default.
• W4284694766 hasRelatedWork W2777867648 @default.
• W4284694766 hasRelatedWork W2786497694 @default.
• W4284694766 hasRelatedWork W2970048128 @default.
• W4284694766 hasRelatedWork W3093422519 @default.
• W4284694766 hasRelatedWork W3153432702 @default.
• W4284694766 hasRelatedWork W3161613553 @default.

• next